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A bidentate Polycomb Repressive-Deubiquitinase
complex is required for efﬁcient activity on
nucleosomes
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Attachment of ubiquitin to lysine 119 of Histone 2A (H2AK119Ub) is an epigenetic mark
characteristic of repressed developmental genes, which is removed by the Polycomb
Repressive-Deubiquitinase (PR-DUB) complex. Here we report the crystal structure of the
Drosophila PR-DUB, revealing that the deubiquitinase Calypso and its activating partner ASX
form a 2:2 complex. The bidentate Calypso–ASX complex is generated by dimerisation of two
activated Calypso proteins through their coiled-coil regions. Disrupting the Calypso dimer
interface does not affect inherent catalytic activity, but inhibits removal of H2AK119Ub as a
consequence of impaired recruitment to nucleosomes. Mutating the equivalent surface on
the human counterpart, BAP1, also compromises activity on nucleosomes. Together, this
suggests that high local concentrations drive assembly of bidentate PR-DUB complexes on
chromatin—providing a mechanistic basis for enhanced PR-DUB activity at speciﬁc genomic
foci, and the impact of distinct classes of PR-DUB mutations in tumorigenesis.
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Epigenetic control of transcription is relevant to all eukar-yotic cell biology and underlies many human diseases.Covalent modiﬁcations to histone proteins (also known as
histone ‘marks’) are one of the most well-established mechanisms
of epigenetic regulation, and are vital to packaging of DNA,
recruiting transcription factors, and ultimately gene transcrip-
tion1. Consequently, the enzymes that attach and remove histone
marks are among the most frequently dysregulated genes in
cancer2,3. Of particular relevance is attachment of ubiquitin to
Histone protein 2A (H2A) on lysine residue 119 (H2AK119Ub)
in humans. H2AK119Ub is one of the most prevalent histone
marks, and is estimated to occur on 5–15% of histones genome-
wide4. In general, H2AK119Ub is characteristic of repressed
developmental genes, and is also tightly linked to levels of other
histone marks such as lysine methylation and acetylation5.
H2AK119Ub is attached to histones by the Really Interesting
New Gene (RING) ubiquitin E3-ligase Polycomb Repressive
Complex 1 (PRC1), and removed by the Polycomb Repressive-
Deubiquitinase (PR-DUB) complex6. The PR-DUB was ﬁrst
characterised in Drosophila melanogaster, where it consists of the
deubiquitinase protein Calypso and a binding partner Additional
Sex Combs (ASX)7. The human PR-DUB complex consists of the
deubiquitinase Breast Cancer type 1 susceptibility protein
(BRCA1)-associated protein-1 (BAP1) and one of three reg-
ulatory ASX-Like proteins (ASXL1–3)7–9. Mutations in BAP1 are
responsible for BAP1 tumour predisposition syndrome (BAP1-
TPDS; OMIM number: 614327), which drives development of
mesothelioma, melanoma, and other neoplasms; sporadic muta-
tions in BAP1 and ASXL1–3 also frequently occur across various
cancer types10–13. BAP1-TPDS is highly penetrant, with ~85% of
heterozygous carriers diagnosed with cancer14. Data from both
mice and humans demonstrate that BAP1 mutations lead to
signiﬁcantly increased risk of malignancy from environmental
carcinogens10. For instance, heterozygous mice with one wild
type and one null BAP1 allele develop mesothelioma at much
lower levels of exposure to asbestos than wild-type animals.
Moreover, BAP1 mutations are found in ~15% of clear-cell renal-
cell carcinomas (CCRCC), and patients bearing such mutations
have a particularly poor prognosis relative to other common
molecular subtypes of CCRCC15.
BAP1 and Calypso each contain a catalytic ubiquitin C-
terminal hydrolase (UCH) domain, and a C-terminal UCH37-like
domain (ULD) (Fig. 1a and Supplementary Fig. 1a) that recruits
the deubiquitinase adaptor (Deubad) domain in ASX, or
ASXL1–3 (refs. 7–9). The overall domain architecture is shared
between the human and Drosophila PR-DUB components, with
the exception of a large insertion (~380 amino acids) in the ULD
domain of BAP1 (Fig. 1a and Supplementary Fig. 1). Finally,
BAP1 and Calypso share a positively charged tail at their C-
termini (Fig. 1a and Supplementary Fig. 1) that has recently been
shown to enhance recruitment of the human PR-DUB complex to
substrate nucleosomes9. No structures of any PR-DUB complex
have been reported, but inferences have been extended from the
human ortholog UCH-L5, which also contains an N-terminal
UCH domain and a C-terminal ULD domain. Recent studies
have shown that substrate binding and catalysis by UCH-L5 is
promoted by the Deubad of the proteasome-associated adapter
Rpn13, or inhibited by the Deubad of the chromatin remodelling
complex subunit INO80G, with the Deubad from each binding
partner stabilising different conformations of the UCH-L5 ULD
domain16,17. While the UCH-L5–Rpn13 complex has provided a
template for PR-DUB catalysis and modelling of some cancer-
derived mutations8,9,18, many outstanding questions remain
unanswered. For instance: it is not clear what the active oligo-
meric state of the PR-DUB is; how the PR-DUB is recruited to
nucleosomes; or why BAP1 exhibits haploinsufﬁciency19,20,
where a single functional copy of BAP1 is not sufﬁcient to protect
from the effects of environmental carcinogens. More broadly it is
unclear why ASXL1 and ASXL2 truncation mutations can cause
either loss-, or gain-of-function;21,22 or why cancers caused by
BAP1 do not overlap with those caused by ASXL1/2 loss23.
With the goal of understanding how PR-DUB activity is
coordinated, we have solved the crystal structure of the Droso-
phila Calypso–ASX complex to a resolution of 3.5 Å. Using size-
exclusion chromatography coupled to multi-angle laser light
scattering (SEC-MALLS), analytical ultracentrifugation (AUC),
small-angle X-ray scattering (SAXS), and chemical crosslinking
we demonstrate that Calypso–ASX forms a higher-order complex
in solution containing two Calypso and two ASX molecules.
Oligomer assembly is mediated by a conserved patch on the
surface of the coiled-coil of Calypso, and disruption of this
interface impairs recruitment of the PR-DUB to nucleosomes and
removal of H2AK119Ub marks. Together, this study suggests a
mechanism where a bidentate PR-DUB complex with two deu-
biquitinases is required for full recruitment and activity on
nucleosomes. Bidentate complex assembly and maximum activity
is most likely to occur at high local PR-DUB concentrations that
arise following targeting to speciﬁc regions of the genome.
Results
Structure of the Drosophila PR-DUB. To understand the
determinants of PR-DUB catalytic activity, we characterised the
complex between Calypso and the Deubad domain of ASX. We
focused on Calypso because it contains the major structural ele-
ments required for activity of the PR-DUB, but lacks the large
insertion present in the ULD domain of BAP1 that is predicted to
be disordered. Following co-expression in Escherichia coli, the
Calypso–ASX complex was crystallised and after extensive opti-
misation the structure was solved to a resolution of 3.5 Å (Sup-
plementary Table 1). Two copies each of Calypso and ASX are
present in the asymmetric unit (Fig. 1b). These are highly similar,
except one copy of the Deubad domain is better deﬁned, owing to
more extensive crystal packing.
In each of the two copies of the Calypso–ASX complex the
globular Calypso UCH domain is linked to the C-terminal ULD
region by a coiled-coil hairpin. The Deubad domain of ASX packs
at the hinge between the coiled-coil and ULD helix of Calypso,
restraining the ULD in a pose protruding away from the active
site (Fig. 1b). The 1:1 topology is similar to that observed for the
related deubiquitinase UCH-L5 bound to its proteasomal
activator Rpn13 (refs. 16,17) (Supplementary Fig. 2, left panel).
Superposition of the trapped UCH-L5~Ub–Rpn13 complex (PDB
code: 4UEL)16 onto the structure shows that the arrangement of
Calypso–ASX builds a composite binding site competent to
accommodate ubiquitin (Fig. 1c). The Deubad of ASX in the
crystal structure is markedly shorter in its C-terminal portion
than the Rpn13 Deubad, a region that is also relatively divergent
between Rpn13 and ASX-type Deubad sequences (Supplementary
Fig. 1d). Whereas Rpn13 consists of seven helices that wrap
around the ULD sequence of UCH-L5, only four are deﬁned for
ASX. It is possible that in situ proteolysis used during crystal
growth may have removed residues 310–340 of the ASX Deubad,
or that the remaining residues of the ASX Deubad adopt alternate
conformations in the crystal. Either scenario would suggest a
degree of conformational ﬂexibility in the C-terminal region of
ASX Deubad.
Characteristics of missense mutations in the human PR-DUB.
Putative driver mutations in PR-DUB components frequently
occur across various cancer types10,24–28. To understand common
missense variants, we mapped mutations in the human Calypso
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ortholog, BAP1, from all tumour samples available in
cBioPortal25,26, onto the Calypso–ASX structure (Fig. 2a and
Supplementary Table 2). Mutations are clearly enriched in key
functional regions of the catalytic domain, with multiple occur-
rences within the active site triad (Cys91, His169, and Asp184),
the ubiquitin binding cleft (Fig. 2a and Supplementary Table 2),
and the crossover-loop that spans the active site of UCH DUBs
and potentially impacts substrate selectivity. Notably Gly185 and
Arg227, located in the active site cleft and at the ubiquitin
interface, respectively, have the highest frequency of mutations. A
range of missense mutations pepper the ~380 amino acid inser-
tion of BAP1, which is important for assembly of large multi-
protein complexes29–33. Some mutations also affect the C-
terminal tail of BAP1, consistent with the importance of this
region in multiple aspects of BAP1 function, including its auto-
deubiquitination, cellular localisation, and nucleosome-binding
properties9,34.
The Drosophila ASX protein has three human orthologs
(ASXL1–3), which also possess an N-terminal Deubad and a C-
terminal plant homeodomain (PHD). Truncating mutations in
ASXL1 and ASXL2 that remove the PHD, but retain the Deubad,
have been linked to both myeloid and myelomonocytic
leukaemias21,22,35, as well as Bohring–Opitz syndrome36. In
recently published work, Sahtoe et al.9 and Peng et al.18
investigated a conserved ‘NEF’ region in the Deubad domain of
ASX-like proteins (residues Asn283–Glu284–Phe285 in ASX)
(Supplementary Fig. 1d)9,18. The crystal structure reveals that the
NEF-motif sits directly adjacent to ubiquitin in a putative
substrate complex (Fig. 2b and Supplementary Fig. 3a). We
noted recurring missense mutations relevant to the ‘NEF’ loop in
cBioPortal: Glu330 in ASXL2 is mutated in breast, bladder, and
urothelial tumours; His315 in ASXL1 in colon, colorectal, lung
cancer, and melanoma patient samples (Supplementary Table 3).
ASXL2 Glu330 is identical in ASX (i.e. Glu284), while the ASX
equivalent to ASXL1 His315 is a positive arginine residue
(Arg288; Fig. 2b and Supplementary Fig. 3a). To ascertain the
functional impact of the observed mutations at these positions,
we introduced E284K, E284Q, and R288N mutations in and
around the ASX NEF-motif (Supplementary Table 3), and
prepared Calypso–ASX complexes. Consistent with the
Calypso–ASX structure, all mutant complexes lost the ability to
hydrolyse Ubiquitin-AMC or a model ubiquitin-peptide sub-
strate, and had reduced capacity to bind ubiquitin in pulldown
assays (Fig. 2c and Supplementary Fig. 3b, c).
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Fig. 1 Crystal structure of the Drosophila PR-DUB complex. a Schematic representing domain structure of human and Drosophila PR-DUB components.
Sequence identity between the UCH and ULD domains of Calypso and BAP1, and between the Deubad domains of ASX and ASXL1 is indicated. FL, full-
length; UCH, ubiquitin C-terminal hydrolase; ULD, UCH37-like domain; ASX, additional sex combs; ASXL1, ASX-like 1; PHD, plant homeodomain (see
Supplementary Fig. 1a). b Structure of the Calypso–ASX complex (PDB code: 6CGA). The UCH and ULD domains of Calypso are coloured orange and blue,
respectively. The Deubad domain of ASX is coloured green. Black arrows indicate the position of the active site cysteine residue in the respective UCH
domains. Deubad (DEU), deubiquitinase adaptor domain (see Supplementary Table 1). c A model of the Calypso~Ub–ASX complex (based on PDB 4UEL;
ref. 16). The Calypso–ASX structure is shown in surface representation and colour coded as in b, while the modelled ubiquitin and the ASX Deubad domain
in chain A are shown as cartoon and coloured grey and green respectively. Ub, ubiquitin
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Together these results illustrate the structural impact of
missense variants in both catalytic and non-catalytic PR-DUB
components that are enriched in tumours, and show that the
crystal structure of Calypso–ASX is a promising model for
predicting the effects of mutations in the human BAP1–ASXL1/2
complexes.
The PR-DUB forms a bidentate complex. A recent study of the
human PR-DUB has reported a 2:1 complex, containing two
BAP1 molecules for every ASX-like molecule9,37. In order to
determine the stoichiometry of Calypso–ASX we ﬁrst analysed
the complex using SEC-MALLS, which showed a molecular
weight of 110 kDa (Fig. 3a). This mass agrees with a complex
consisting of two Calypso and two ASX molecules, which would
have a theoretical mass of 109 kDa. To validate the 2:2 complex
using an independent method we used AUC. Analysis of
sedimentation velocity experiments using the c(s) method
showed a homogeneous population of the 2:2 complex at a
concentration of 40 μM, with an s(20,w) of 5.78 S (Fig. 3b and
Supplementary Fig. 4a, c). Sedimentation equilibrium experi-
ments performed at the same concentration showed a mole-
cular weight of 112.9 kDa (±0.3 kDa), which is again consistent
with a 2:2 Calypso–ASX complex (Supplementary Fig. 4b). At
decreasing protein concentrations (1–18 µM), there is a shift in
the sedimentation coefﬁcient to smaller values (Fig. 3c), which
is consistent with mass-action dissociation of the 2:2
Calypso–ASX oligomer (see Supplementary Fig. 4c for van
Holde–Weischet analysis).
A dissociation constant in the µM range for the 2:2 complex
suggests that the bidentate PR-DUB is unlikely to be constitutive.
In contrast, 1:1 interactions between deubiquitinase and ASX-like
proteins are 100–1000-fold tighter (KD ~6–18 nM)16,17. Thus,
there appears to be two layers of PR-DUB assembly: a tight
interaction between a deubiquitinase and an ASX-like protein,
and a more transient higher-order complex that could represent
an additional mechanism for regulating PR-DUB activity.
PR-DUB oligomerisation via the coiled-coil hairpin. To dissect
higher-order oligomerisation of the PR-DUB we analysed various
interaction surfaces within crystal contacts of the Calypso–ASX
complex. Three possible interfaces capable of building a 2:2 oli-
gomer from the Calypso–ASX unit were identiﬁed by PISA
(Protein, Interfaces, Structures and Assemblies)38 (Supplemen-
tary Fig. 5a, top row, and Supplementary Table 4; interfaces #3,
#4, and #5). We designed mutations at each of the three inter-
faces, and tested their oligomerisation using analytical SEC.
Mutation of the interface formed by the coiled-coil hairpin of
Calypso clearly shifted the peak of Calypso(L340A)–ASX,
whereas Calypso–ASX complexes bearing mutations at all other
crystallographic interfaces eluted in an identical position to the
wild-type complex (Fig. 4a). Having established that oligomer-
isation of Calypso–ASX occurs via the coiled-coil hairpin in
Calypso, we targeted additional residues at this interface. We
introduced M288R and N292R mutations (Supplementary
Fig. 5a, top row; interface #5) and prepared Calypso–ASX com-
plexes. Wild type and mutant proteins were then tested in
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Fig. 2 Characteristics of missense mutations in the human PR-DUB. a Model of the Calypso~Ub–ASX complex generated as described in Fig. 1c, with
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analytical SEC experiments. Consistent with our previous data,
the elution proﬁles of Calypso(M288R)–ASX and Calypso
(N292R)–ASX were considerably shifted compared to the wild-
type complex (Fig. 4b).
To characterise the contribution of each of these residues to
Calypso–ASX oligomerisation, we performed SEC-MALLS
experiments. Mutation of Leu340 and Asn292 to alanine and
arginine residues respectively resulted in the formation of a 1:1
PR-DUB complex, with a molecular weight of 60 kDa (Fig. 4c).
The Calypso(M288R)–ASX mutant exhibited an intermediate
oligomeric state, with a molecular weight of 76 kDa (Fig. 4c).
These results clearly indicate that Leu340 and Asn292 play a
major role in Calypso dimerisation, and that mutation of Met288
also destabilises interactions at the 2:2 PR-DUB dimer interface.
The arrangement mediated by hydrophobic interactions
between Leu340 and Met288 from the two Calypso coiled-coil
hairpins (Supplementary Fig. 5) creates an unusual elongated 2:2
complex, which we investigated in solution using SEC-SAXS.
Guinier analyses showed that the Calypso–ASX complex was
monodisperse and free of aggregation, with a calculated Dmax of
125 Å (Fig. 4d, Supplementary Fig. 5f, and Supplementary
Table 5). This was consistent with a 2:2 Calypso–ASX complex
being present in solution, in line with SEC-MALLS and AUC
(Fig. 3). To compare experimental and theoretical scattering
proﬁles, we modelled and energy minimised several loops that
were not deﬁned by electron density in the crystal structure.
Having generated a complete model (Supplementary Fig. 5g),
scattering proﬁles were an excellent ﬁt for the oligomers formed
through either the Calypso UCH and Calypso coiled-coil hairpin
(Supplementary Fig. 5a, bottom row; interfaces #3 and #5)
whereas interface #4 led to higher Chi values and poorer ﬁts
(Supplementary Fig. 5a, bottom row).
Finally, we employed chemical crosslinking to interrogate the
higher-order Calypso–ASX complex. Treatment with increasing
concentrations of bis(sulfosuccinimidyl)suberate (BS3) (Fig. 4e),
or with ﬁxed concentrations of BS3 over increasing time periods
(Supplementary Fig. 5h), led to crosslinked complexes that could
be resolved by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE). The ﬁrst and most prominent
complex migrated at ~55 kDa, consistent with a covalent 1:1
Calypso–ASX complex. A second tight group of crosslinked
bands migrated with a molecular weight of approximately 150
kDa. Performing equivalent crosslinking experiments with
Calypso(L340A)–ASX gave rise to a crosslinked band of ~55
kDa, but no higher molecular weight species (Fig. 4e and
Supplementary Fig. 5h). Although SDS-PAGE mobility was
slightly aberrant relative to a theoretical mass of 109 kDa for
the 2:2 complex, the clearest explanation for this proﬁle is that the
high molecular weight species contain Calypso–Calypso cross-
links. These crosslinks are speciﬁc to wild-type Calypso–ASX
rather than the L340A protein, and are consistent with L340A
disrupting the Calypso–Calypso coiled-coil interface, but not
disrupting the ability of Calypso to bind ASX.
Together, orthogonal biophysical and biochemical methods
show that the bidentate PR-DUB complex is formed through an
interface on the Calypso coiled-coil hairpin—in effect a Calypso
dimer with each molecule independently able to bind one ASX
Deubad domain.
Bidentate complex assembly promotes activity on nucleosomes.
The arrangement of a 2:2 Calypso–ASX complex bridged by the
Calypso coiled-coil creates an elongated structure with a large
cleft separating the two UCH domains and the Deubad of ASX.
To test whether mutations in the Calypso coiled-coil hairpin
affect the intrinsic ubiquitin hydrolase activity of the PR-DUB, we
ﬁrst tested wild type and L340A Calypso–ASX proteins against a
model ubiquitin-peptide substrate. Both complexes could
hydrolyse the model substrate at comparable rates (Supplemen-
tary Fig. 3b). We then used Ubiquitin-AMC cleavage assays to
determine the Michaelis–Menten constant for both wild type and
L340A proteins. There was no signiﬁcant difference in KM
between the constructs (Fig. 5a), showing that mutation at
Leu340 did not affect the correct folding of the complex or its
catalytic activity.
Having established that disrupting the 2:2 Calypso–ASX
complex into individual Calypso–ASX units does not affect its
intrinsic catalytic activity, we next sought to test whether
bidentate complex assembly was necessary for activity on its
primary biological substrate, H2AK119Ub nucleosomes. We
generated recombinant nucleosomes by co-expression in E. coli,
and used the PRC1 E3-ligase pair Ring1b-Bmi1 to speciﬁcally
ubiquitinate Histone 2A39. In order to visualise and quantitate
assays we employed N-terminal 5-iodoacetamidoﬂuorescein (5-
IAF)-labelled ubiquitin. While wild-type Calypso–ASX robustly
deubiquitinated H2AK119Ub, the activity of the Calypso
(L340A)–ASX complex was severely attenuated (Fig. 5b). Per-
forming equivalent experiments with the Calypso(M288R)–ASX
and Calypso(N292R)–ASX proteins also resulted in decreased
activity (Fig. 5b). Thus, bidentate complex assembly is crucial for
the ability of the PR-DUB complex to remove H2AK119Ub from
nucleosomes, even though it does not impair intrinsic catalytic
activity.
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To determine if the bidentate structure is a common feature of
other PR-DUB complexes, we generated an alignment of the
coiled-coil hairpin of nine different BAP1 and Calypso-like DUB
sequences (Supplementary Fig. 6a). Consistent with an important
role in oligomerisation (Fig. 4a–c), the residues corresponding to
Calypso Leu340, Met288, and Asn292 are highly conserved
throughout Calypso/BAP1-type DUBs. In order to determine if
the coiled-coil hairpin is functionally conserved in the human
PR-DUB complex, the residue in BAP1 corresponding to Calypso
Leu340 (i.e. Leu635) was mutated to alanine. Wild type and
mutant BAP1–ASXL1 complexes were ﬁrst compared in
Ubiquitin-AMC cleavage assays. As previously shown for the
corresponding Calypso–ASX proteins, we did not detect a
noticeable difference in KM between the two BAP1–ASXL1
constructs (Supplementary Fig. 6b), demonstrating that mutation
at Leu635 did not induce structural changes in BAP1 that could
affect its catalytic activity. Wild type and L635A BAP1–ASXL1
complexes were then tested for their ability to cleave ubiquitin
from H2AK119Ub nucleosomes. Consistent with a conserved role
for Calypso/BAP1 dimerisation, wild-type BAP1–ASXL1 was able
to deubiquitinate H2AK119Ub, whereas the BAP1
(L635A)–ASXL1 complex had decreased activity (Fig. 5c).
Mutation of the BAP1 residue corresponding to Calypso
Asn292 (i.e. Asn251) showed a moderate reduction in the
catalytic activity of the BAP1(N251R)–ASXL1 complex compared
to wild-type protein (Fig. 5c).
Overall, these analyses demonstrate that oligomerisation of
Calypso–ASX via the coiled-coil region in Calypso is required for
deubiquitination of H2AK119Ub, and that the same surface is
required for efﬁcient activity of BAP1–ASXL1. We next sought to
explain why the bidentate 2:2 complexes acted more efﬁciently on
H2AK119Ub nucleosomes even though the inherent enzymatic
activities of 1:1 or 2:2 complexes are equivalent (Fig. 5a and
Supplementary Fig. 6b).
PR-DUB oligomerisation enables efﬁcient nucleosome bind-
ing. Sahtoe et al.9 recently reported that the C-terminal positively
charged tail of BAP1 is crucial for recruitment of the human PR-
DUB complex to nucleosomes. Calypso also contains a homo-
logous stretch of positively charged residues C-terminal to its
ULD domain (Fig. 1a and Supplementary Fig. 1a, c). We hypo-
thesised that an oligomeric DUB complex—containing two copies
of either BAP1 or Calypso—would have two positively charged
tails to promote recruitment of the PR-DUB to nucleosomes.
Accordingly two suitably oriented tails would increase avidity for
nucleosomes and thus explain increased activity relative to basal,
monodentate, PR-DUB activity, as shown in Fig. 5.
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NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06186-1 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3932 | DOI: 10.1038/s41467-018-06186-1 | www.nature.com/naturecommunications 7
To ﬁrst verify if the C-terminal positively charged tail of
Calypso is required for efﬁcient recruitment of the Drosophila
PR-DUB to nucleosomes, we performed electrophoretic mobility
shift assays. While wild-type Calypso–ASX lacking the C-terminal
tail (here referred to as WTno tail) did not bind nucleosomes, the
wild-type complex bearing the C-terminal tail (referred to as WT)
was capable of shifting the nucleosome core particles in a
concentration-dependent manner (Fig. 6a). In addition, we tested
wild-type Calypsono tail–ASX and BAP1no tail–ASXL1 complexes
for their ability to cleave ubiquitin from nucleosomes mono-
ubiquitinated at H2AK119. Consistent with our binding experi-
ments, as well as with a previous study by Sahtoe et al.9, both
complexes showed impaired activity (Supplementary Fig. 6c).
This indicates that, similarly to BAP1, the positively charged tail
in Calypso is essential for interaction of the Drosophila PR-DUB
with nucleosomes.
Having established the importance of the C-terminal tail in
Calypso–ASX recruitment to nucleosomes, we then investigated if
the Calypso-mediated bidentate PR-DUB complex was required
for binding to its biological substrate. Consistent with activity
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assays (Fig. 5b), wild-type Calypso–ASX was able to efﬁciently
retard mobility of the nucleosome band, whereas the Calypso
(L340A)–ASX complex had reduced ability to bind nucleosomes
and therefore induced less nucleosome mobility shift at
equivalent concentrations (Fig. 6b). Performing equivalent
experiments with the corresponding BAP1–ASXL1 complexes
demonstrated that wild-type BAP1–ASXL1 readily shifted the
nucleosome band, whereas the L635A BAP1–ASXL1 complex had
a dramatically impaired ability to induce nucleosome mobility
shift at the same concentrations (Fig. 6c).
These experiments are consistent with the hypothesis that a
bidentate 2:2 PR-DUB complex is most efﬁciently recruited to
nucleosomes by virtue of having two positively charged C-
terminal tails, leading to enhanced activity and efﬁcient removal
of H2AK119Ub (Fig. 6d). The bidentate Calypso–ASX complex
from the crystal structure places two C-terminal tails on the same
side of the PR-DUB, with two DUB active sites approximately 60
Å apart. Given the symmetry of histone proteins within a
nucleosome—with two Histone 2A molecules sitting on opposite
sides of the DNA but generally adjacent one another—a bidentate
PR-DUB is well-suited for recruitment to individual nucleosomes,
and subsequent removal of ubiquitin marks (Fig. 6e).
Model of PR-DUB regulation by deubiquitinase oligomerisa-
tion. The ﬁnding that a bidentate PR-DUB complex with two
DUB components has enhanced activity on nucleosomes allows
us to propose a revised model for regulation of PR-DUB activity
(Fig. 7a). Because DUB–ASX interactions are relatively tight (KD
~6–18 nM)16,17 and bidentate complex assembly is relatively low
afﬁnity (dissociating in the 1–18 µM range; Fig. 3c), it is likely
that the PR-DUB predominantly exists as a 1:1 complex in the
nucleus with low basal activity on H2AK119Ub nucleosomes.
Enrichment of the 1:1 complex in speciﬁc regions of the genome,
either by direct interaction of the PHD domain with nucleosomes
or via indirect recruitment of the PR-DUB by other binding
partners, would enhance the local concentration such that DUB
(Calypso/BAP1) oligomerisation and bidentate higher-order
complex formation becomes favoured. Once the bidentate com-
plex forms, the two C-terminal tails of BAP1/Calypso are brought
into an optimal orientation for enhanced nucleosome recruitment
and removal of H2AK119Ub. Through such a mechanism max-
imal PR-DUB activity can be focussed speciﬁcally within the
genome. Conversely, activity of the PR-DUB outside of these foci
is low, and can be antagonised by PRC1-based H2A
ubiquitination.
The proposed model accounts for distinct classes of human
PR-DUB mutations that drive carcinogenesis. For instance,
ASXL1 truncations that lead to a loss of the C-terminal PHD
domain (Fig. 7b, [1]) can globally erase H2AK119Ub39,
potentially because these ASXL1 molecules can moderately
activate BAP1 with their Deubad domains but fail to locally
concentrate the PR-DUB in particular areas of the genome.
Heterozygous loss of BAP1 (Fig. 7b, [2]) would reduce overall
levels of BAP1 protein, disfavouring bidentate complex assembly
and decreasing speciﬁc activity. In a similar vein, mutations that
truncate the BAP1 C-terminal tail (Fig. 7b, [3]) would disfavour
efﬁcient nucleosome recruitment, even in the presence of two
BAP1 protomers. Finally, missense mutations such as those
depicted in Fig. 2 would directly block activity of either
monodentate or bidentate complexes (Fig. 7b, [4]) and disrupt
homoeostasis of genome-wide H2AK119Ub.
Discussion
The PR-DUB complex plays a vital role in regulating
H2AK119Ub histone marks, and mutations in human PR-DUB
genes lead to a spectrum of malignancies. Here we present the
ﬁrst PR-DUB structure from any organism. The structure pro-
vides two major insights—it clariﬁes how the Deubad protein
ASX (and its human homologues ASXL1–3) stimulates the deu-
biquitinase activity of Calypso (and BAP1 in humans); and pro-
vides a model to explain how the Calypso–ASX complex forms
higher-order oligomers that are crucial for its biological activity.
Both aspects contribute to a more complete understanding of
how PR-DUB activity is regulated in multicellular organisms, and
how mutations in the PR-DUB disrupt normal regulation to drive
cancer development.
This work provides a structural basis upon which to interpret
previous studies showing that the ASXL1/2 Deubad domains bind
tightly to BAP1, and activate the complex by forming a composite
binding site for ubiquitin8,9. The structure of Calypso–ASX is
reminiscent of the activated deubiquitinase complex observed for
UCH-L5 bound to the Deubad domain of Rpn13 (Supplementary
Fig. 2, left panel) (PDB codes: 4UEM and 4WLQ), rather than the
inhibitory Deubad INO80G bound to the same UCH DUB
(Supplementary Fig. 2, right panel) (PDB codes: 4UF5 and
4WLP)16,17. Because UCH-L5–Rpn13 structures with and with-
out ubiquitin bound are available, we could model an active
intermediate with ubiquitin bound in the cleft of Calypso–ASX
(Fig. 1c). Mutagenesis analyses performed in this study (Fig. 2c
and Supplementary Fig. 3b, c), as well as in previous works8,9,18
Fig. 6 PR-DUBs oligomerisation enables efﬁcient nucleosome recruitment. a Electrophoretic mobility shift assays comparing the ability of wild-type
Calypsono tail–ASX and Calypso–ASX complexes to bind nucleosomes at varying protein concentrations (0.5, 1, 2, 4, 8 μM). Recombinant nucleosomes
reconstituted with a 220 bp Widom 601 DNA sequence labelled at the 5′ with an IRDye®700 were used to visualise nucleosomes. b Electrophoretic
mobility shift assays testing the binding of wild type and L340A Calypso–ASX proteins to nucleosomes at increased protein concentrations (as for panel a).
Bands corresponding to the shifted nucleosome particle (indicated as shifted NCP) were quantiﬁed. Quantitated triplicates corresponding to three
independent experiments are shown on the right, with a line passing through the mean. c Electrophoretic mobility shift assays comparing the ability of wild
type and L635A BAP1–ASXL1 complexes to bind nucleosomes at different protein concentrations (0.1, 0.2, 0.5, 1, and 2 μM). Recombinant nucleosomes
were reconstituted as outlined in a. Experiments were quantiﬁed as described in b. d Schematic representation of the mechanisms that underpin PR-DUB
recruitment and activity on nucleosomes. In the absence of the C-terminal positively charged tails (left), the oligomeric PR-DUB complex cannot be
recruited to nucleosomes, resulting in a total loss of activity and maintenance of the H2AK119Ub mark. The 1:1 PR-DUB complex (middle), despite the
presence of the C-terminal tail, has reduced afﬁnity for nucleosomes and hence limited ability to deubiquitinate H2AK119Ub. Only a PR-DUB complex that
bears two C-terminal tails and that has full ability to form a bidentate complex (right) can be efﬁciently recruited to nucleosomes, thereby resulting in
increased activity. e Scale model for bidentate recruitment of the Calypso–ASX complex to H2AK119Ub nucleosomes. The Calypso dimer and ubiquitin are
shown in surface representation, while the ASX Deubad domains are shown as cartoon; the surface of the nucleosome particle is represented as
electrostatic potential. The C-terminal positively charged tails of the two Calypso molecules are shown in blue. Black arrows indicate the distances between
the two Calypso active sites as well as between the two mono-ubiquitinated Histone 2A Lys119 residues of the nucleosome particle
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demonstrate that mutations at the composite interface between
DUB, Deubad, and ubiquitin have a dramatic effect on the ability
of the PR-DUB to interact with ubiquitin, ultimately leading to
impaired activity. These ﬁndings, coupled with the recurrence of
the same mutations in human cancers25,26 (Supplementary
Table 3), underline the high sensitivity of this juncture for PR-
DUB activity.
A striking aspect of this study is that Calypso–ASX forms
stable 2:2 oligomers in solution, in which two Calypso–ASX units
interact via the coiled-coil region of Calypso. Several lines of
evidence suggest that the human PR-DUB also forms higher-
order oligomers, and a conserved mode of deubiquitinase oligo-
merisation is consistent with our ﬁnding that mutating the coiled-
coil of BAP1 reduces activity on H2AK119Ub nucleosomes
(Fig. 5b, c). In vitro experiments have previously shown that
BAP1 oligomerises and BAP1–ASXL1 can form a complex with
apparent 2:1 stoichiometry9,37, while mass spectrometry and
biochemical studies have shown that the PR-DUB can consist of
BAP1–ASXL1 or BAP1–ASXL2 complexes8,37. It remains to be
seen whether the equimolar (2:2) DUB–ASX stoichiometry we
observe is conserved in humans but obscured by redundancy of
human PR-DUB components. There is also scope for the BAP1-
speciﬁc insert to inﬂuence the makeup of the PR-DUB in
humans, or its stoichiometry, relative to the simpler two-
component system of Drosophila. Our structural and biochem-
ical analyses now show that a major effect of PR-DUB dimer-
isation is to place two positively charged tails in close proximity,
mediating bidentate nucleosome recruitment. Such an arrange-
ment is crucial to promote higher afﬁnity interaction with
nucleosomes by increasing avidity, and ultimately allowing
efﬁcient removal of H2AK119Ub (Figs. 6d and 7a). Intriguingly,
the arrangement of the Calypso dimer places the two active sites
approximately 60 Å apart, which would allow it to span a single
mononucleosome and access two Histone 2A Lys119 residues
(Fig. 6e). While spanning a single nucleosome is attractive, it is
also possible that the bidentate complex bridges multiple
nucleosomes. In either scenario increased local concentration of
the PR-DUB would drive oligomerisation and efﬁcient removal of
H2AK119Ub marks from speciﬁc genomic foci, thereby leading
to decompaction of the chromatin ﬁbres and enhancement of
gene expression.
BAP1 and ASXL1/2 undergo both missense and nonsense
mutations in various cancers and exhibit hallmarks of hap-
loinsufﬁciency, whereby mutations even in a heterozygous form
have deleterious effects20. In this sense, the requirement of
higher-order PR-DUB oligomerisation for efﬁcient activity on
nucleosomes is highly relevant to cancer epigenetics. The mod-
erate afﬁnity of Calypso dimerisation suggests that activity could
be particularly sensitive to protein concentration—mutation of
one gene copy could effectively deplete the activity of the
remaining translated wild-type protein. A major outstanding
question within the model illustrated in Fig. 7a is the exact
mechanism that drives PR-DUB enrichment in particular regions
of the genome. Several factors could be at play: for instance (i) the
C-terminal PHD domain of ASX-like proteins may recognise
speciﬁc histone marks; or (ii) the PR-DUB may be localised
indirectly by other binding partners. The former mechanism is
suggested by the general role of PHD domains as histone readers
and studies demonstrating dysregulation of H2AK119Ub upon
truncation of the ASXL1/2 PHD domains;21,22,40 the latter
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Fig. 7 Model for PR-DUB regulation and its disruption in human cancers. a The 1:1 PR-DUB complex is ﬁrst targeted to nucleosomal arrays either via the
PHD domain of ASX-like proteins or through interactions with transcription factors and/or other binding partners (left). Enrichment of multiple 1:1
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recruitment, and activity on nucleosomes via multiple mechanisms
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mechanism is supported by data showing signiﬁcant enrichment
of BAP1 at E-twenty six (Ets) and Speciﬁc protein 1 (Sp1) tran-
scription factor-binding sequences32 or that ASXL1 participates
in direct recruitment of the PRC2 complex to speciﬁc genomic
loci17. We anticipate future structural and biochemical studies
will enable further insight. Finally, it remains to be seen how the
bidentate complex may affect deubiquitination of other PR-DUB
substrates—for instance BAP1 has been proposed to remove
ubiquitin from its own C-terminal tail, as well as Host Cell
Factor-1 (HCF-1; which binds within the BAP1-speciﬁc
insert) and Ube2O29,30,34, both of which are highly relevant to
the role of the PR-DUB in cancers.
In summary, this study provides a template for understanding
PR-DUB function in both normal and cancer biology. We show
that the Drosophila PR-DUB complex provides an excellent
structural model to understand the impact of missense mutations
in the human complex, and that a 2:2 PR-DUB complex is
markedly more efﬁcient at removing H2AK119Ub—the latter
ﬁnding suggests a mechanism by which PR-DUB is focussed in
particular genomic regions in healthy cells, and disrupted by
multiple mechanisms to drive malignancy.
Methods
Plasmids and cloning. To generate a co-expression construct for Calypso–ASX,
the DNA sequences of Calypso (corresponding to residues 43–404) and ASX
(residues 207–340) were fused together with the linker sequence that connects the
ﬁrst and the second multiple cloning site in the pET-Duet1 vector (Nova-
gen). Residues 258–270 in ASX, which are not conserved in the human ASXL
proteins and are predicted to be disordered, were omitted from this co-expression
construct. 5′-(CAGGGACCCGGT) and 3′-(TAACCGGGCTTCTCCTCG) over-
hangs, required for Ligation-Independent Cloning (LIC), were also introduced. The
resulting co-expression construct was synthesised by Integrated DNA Technology
(IDT) and cloned into an N-terminal His6 tag expression vector of the NKI LIC
Suite41. The same construct was subsequently used to introduce the C-terminal
positively charged tail in Calypso. Brieﬂy, site-directed mutagenesis was ﬁrst
employed to replace the STOP codon of Calypso with a KpnI restriction site.
Following linearisaton of the vector, the DNA sequence corresponding to the
positively charged tail of Calypso (residues 405–471; synthesised by IDT) was
introduced by Gibson assembly42. A co-expression construct encoding the RING
domains of mouse Ring1B (residues 1–159) and Bmi1 (residues 1–109)39 was
synthesised and cloned as described for Calypso–ASX, with the exception that an
N-terminal glutathione-S-transferase (GST)-His6 tag expression vector was used.
Ubiquitin-H2Atail, in which the sequence of wild-type Ubiquitin was linked to the
C-terminal tail of Histone 2A (residues 120–130), was synthesised by IDT and
cloned into pET-3a (Novagen) using NdeI and BamHI. Constructs encoding the
human E1 enzyme Ube1 (Addgene plasmid # 34965)43 and Xenopus laevis histones
(Addgene plasmid # 66890)44 were purchased from Addgene, while the Widom
601 DNA sequence45 was synthesised by IDT. The sequence of the Widom 601
DNA used in this study is as follows (randomly chosen nucleotide sequences are in
small case letters while the EcoRV restriction sites are underlined and in italics):
gcgtaaGATATCATCGATGGACCCTATACGCGGCCGCCCTGGAGAATCC
CGGTGCCGAGGCCGCTCAATTGGTCGTAGACAGCTCTAGCACCGCTTAA
ACGCACGTACGCGCTGTCCCCCGCGTTTTAACCGCCAAGGGGATTACT
CCCTAGTCTCCAGGCACGTGTCAGATATATACATCCTGTGCATGTATTGA
ACAGCGACCTGATGATATCgcgtaa
Wild-type Ubiquitin was cloned into pET-3a using NdeI and BamHI46. To
allow labelling of Ubiquitin with 5-iodoacetamidoﬂuorescein (5-IAF) (Thermo
Fisher Scientiﬁc Molecular Probes), site-directed mutagenesis was used to
introduce a methionine and cysteine residues before the beginning of the Ubiquitin
sequence, resulting in Met-Cys-Ubiquitin47. UbcH5bC21S/C107S/C111S (3C/S) was
cloned into pGEX-6P-3 (GE Healthcare) with BamHI and EcoRI restriction sites.
To generate constructs for insect cells expression, the DNA sequences of
Calypso (residues 43–471) and BAP1 (residues 1–729 or 1–712) were cloned into a
pFastBac expression vector modiﬁed to incorporate an N-terminal His6 tag
followed by a 3C protease cleavage site with LIC compatible overhangs, while the
DNA sequences corresponding to the Deubad domains of ASX (residues 207–340)
and ASXL1 (residues 247–366) were cloned into an equivalent N-terminal StrepII
tag pFastBac vector. Calypso and BAP1 dimer interface mutants (i.e. Calypso
L340A, M288R and N292R; BAP1 L635A and N251R) were cloned in the same
manner as wild-type constructs. Positive clones were selected, and the
corresponding wild type and mutant Calypso–ASX and BAP1–ASXL1 complexes
assembled into pBig1a for co-expression by Gibson assembly42. Following
transformation of the Gibson mixtures into DH10BAC cells (Life Technologies), a
second round of selection was used to isolate the clones containing the assembled
complexes.
All point mutations were introduced using the one-step site-directed
mutagenesis protocol48.
Protein expression and puriﬁcation. Calypso–ASX wild type and mutant com-
plexes were co-expressed with an N-terminal His6 tag in E. coli BL21 (DE3) cells
(Novagen). Cells were grown at 37 °C in Luria-Bertani (LB) medium to an OD600 of
approximately 0.6, then induced with 0.2 mM isopropyl-β-D-1-thiogalactopyr-
anoside (IPTG) and grown at 18 °C overnight (O/N). Bacterial pellets were
resuspended in 50 mM HEPES pH 7.5, 10% (v/v) glycerol, 10% (w/v) sucrose,
50 mM NaCl, and 5 mM imidazole. Cells were lysed by sonication using a Soniﬁer
(Heat Systems Ultrasonics) instrument and the soluble fractions bound to
Ni2+-nitrilotriacetic acid (NTA) resin (Sigma-Aldrich) for 1 h at 4 °C on a rotary
mixer, after which the resins were washed four times with 50 mM HEPES pH 7.5,
10% (v/v) glycerol, 10% (w/v) sucrose, 300 mM NaCl, and 5 mM imidazole. Protein
complexes were eluted with the same buffer containing 300 mM imidazole. To
release Calypso variants from the His6 tag, the recovered fractions were combined
and 3C protease and 5 mM dithiothreitol (DTT) added. Samples were incubated
O/N at 4 °C and cleavage was monitored by SDS-PAGE analysis. Calypso–ASX
complexes were then diluted ten times in 50 mM HEPES pH 7.5 and 5 mM NaCl,
and loaded onto a 5 mL HiTrap QHP column (GE Healthcare) pre-equilibrated in
the same buffer. A linear 25 mL gradient, from 0.005 to 1 M NaCl, was used to elute
the proteins. The recovered Calypso–ASX complexes were ﬁnally puriﬁed on a
Superdex 200 10/300 column (GE Healthcare) in 20 mM HEPES pH 7.5 and
100 mM NaCl.
For the expression and puriﬁcation of the protein complexes derived from
insect cells, the Bac-to-Bac baculovirus expression system (Invitrogen) was used to
generate baculovirus stocks for wild type and mutant Calypso–ASX and
BAP1–ASXL1 proteins according to the manufacturer’s protocol, with the
exception that FuGENE 6 (Promega) was used for transfection. The Trichoplusia ni
(Tni) (Expression Systems) cell line was infected with the obtained baculovirus
stocks co-expressing wild type and dimer interface mutants (i.e. L340A, M288R,
and N292R) Calypso43–471–ASX207–340 complexes, as well as with baculoviruses for
the co-expression of the N251R BAP11–729–ASXL1247–366 and wild-type
BAP11–712–ASXL1247–366 (later referred to as BAP1no tail–ASXL1) proteins.
Spodoptera frugiperda (Sf) 9 (Expression Systems) cells were used for the co-
expression of the wild type and L635A complexes in BAP11–729–ASXL1247–366.
Cells were infected in log phase growth at a density of approximately 1.0 × 106
cells/mL. Following infection, cells were grown in ESF921 medium (Expression
Systems) and incubated at 27 °C, 125 r.p.m., for either 48 h (Tni) or 72 h (Sf9)
before being harvested. Cell pellets were resuspended in 50 mM Tris-HCl pH 8.0,
10% (v/v) glycerol, 150 mM NaCl, and 10 mM imidazole supplemented with 10 μg
DNaseI (Applichem). Following incubation on ice for 30 min, cells were lysed using
a Sonics (Vibra Cell) instrument, and the soluble fractions bound to Ni2+-NTA
resin as described above. Wild type and mutant Calypso–ASX and BAP1–ASXL1
complexes were eluted with 50 mM Tris-HCl pH 8.0, 10% (v/v) glycerol, 150 mM
NaCl, and 500 mM imidazole. Recovered fractions were pooled and dialysed O/N
against 20 mM HEPES pH 7.5 and 100 mM NaCl.
The Ring1B–Bmi1 complex was co-expressed with an N-terminal GST-His6 tag
in E. coli Rosetta 2 (DE3) cells (Novagen). Cells were grown at 37 °C in LB medium
until OD600 reached 0.6, then induced with 0.2 mM IPTG and 0.1 mM ZnCl2. After
induction, cells were grown at 28 °C for 4 h. Bacterial pellets were resuspended in
50 mM MES pH 6.5 and 200 mM NaCl, lysed, and the soluble fractions bound to
glutathione (GSH) Sepharose resin (GE Healthcare) for 1 h at 4 °C on a rotary
mixer. The GST-His6 tag was removed by O/N incubation with 3C protease and
5 mM DTT. Upon completion of the cleavage, the Ring1B–Bmi1 complex was
washed off the resin using a hand-held column (Bio-Rad) and puriﬁed on a
Superdex 75 10/300 column (GE Healthcare) in 20 mM MES pH 6.5 and 100 mM
NaCl.
Ubiquitin-H2Atail was expressed as untagged construct in E. coli BL21 (DE3)
cells. Cells were grown at 37 °C in LB medium to an OD600 of approximately 0.6,
then induced with 0.2 mM IPTG and grown at 37 °C for 4 h. Bacterial cells were
sonicated in 30 mM MES pH 6.5, 10 mM NaCl, and 1 mM
ethylenediaminetetraacetic acid (EDTA), and the soluble protein fractions loaded
onto a 5 mL HiTrap SPHP column (GE Healthcare) pre-equilibrated in the same
buffer used for lysis. The fusion protein was then eluted with a linear 25 mL
gradient, from 0 to 1 M NaCl, and further puriﬁed on a Superdex 75 10/300
column (GE Healthcare) in 20 mM Tris-HCl pH 7.5 and 100 mM NaCl.
Human Ube1 was expressed with an N-terminal His6 tag in E. coli BL21 (DE3)
cells43. Cells were grown at 37 °C in LB medium to an OD600 of 0.6, then induced
with 0.2 mM IPTG, and grown at 18 °C O/N. Bacterial pellets were lysed in 20 mM
Tris-HCl pH 8.5, 100 mM NaCl and 5 mM imidazole, and the supernatant was
loaded onto a 5 mL HisTrap column (GE Healthcare). A linear 50 mL gradient,
from 5 to 250 mM imidazole, was then applied. Fractions containing hUbe1 were
recovered and ﬁnally puriﬁed on a HiLoad Superdex 200 16/60 column (GE
Healthcare) in 20 mM Tris-HCl pH 7.5 and 150 mM NaCl.
UbcH5b3C/S was expressed with an N-terminal GST tag in E. coli BL21 (DE3)
cells. Cells were grown at 37 °C in LB medium until OD600 reached 0.6, then
induced with 0.2 mM IPTG and grown at 37 °C for 4 h. Bacterial pellets were lysed
in phosphate-buffered saline (PBS; 10 mM Na2HPO4, 1.8 mM KH2PO4, 140 mM
NaCl, and 2.7 mM KCl, pH 7.4), and the soluble fractions bound to GSH Sepharose
resin for 1 h at 4 °C on a rotary mixer. The GST tag was removed by O/N
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incubation with 3C protease and 5 mM DTT. Upon completion of the cleavage,
UbcH5b3C/S was recovered and further puriﬁed on a HiLoad Superdex 75 16/60
column (GE Healthcare) in PBS.
Wild-type and Met-Cys-Ubiquitin variants were expressed as untagged
constructs in E. coli BL21 (DE3) cells46. Cells were grown at 37 °C in LB medium to
an OD600 of 0.6, then induced with 0.2 mM IPTG and grown at 37 °C for 4 h.
Bacterial cells were sonicated in 50 mM NH4C2H3O2 pH 4.5 and 1 mM EDTA, and
the supernatant was incubated for 1 h at 60 °C. Following clariﬁcation, the soluble
fraction was puriﬁed on a 5 mL HiTrap SPHP column and proteins were eluted
with a linear 25 mL gradient, from 0 to 1 M NaCl. Wild-type Ubiquitin used in
pulldown experiments was puriﬁed on a HiLoad Superdex 75 16/60 column in
20 mM Tris-HCl pH 7.5 and 150 mM NaCl. Whereas Met-Cys-Ubiquitin used in
subsequent labelling steps was puriﬁed on the same column in HBS buffer (50 mM
HEPES pH 7.4, 150 mM NaCl, and 5 mM MgCl2). To allow labelling47 with 5-IAF,
the peak fractions were pooled and incubated with 4 mM 5-IAF for 1 h at room
temperature. The labelled protein was then separated from excess dye by using a
10 mL HiTrap desalting column (GE Healthcare), pre-equilibrated in HBS buffer.
Labelled Ubiquitin was incubated O/N at room temperature to allow unconjugated
protein to form disulphide-linked dimers. The mixture was ﬁnally separated on a
HiLoad Superdex 75 16/60 column in HBS.
Puriﬁcation of recombinant histones. Expression and puriﬁcation of recombi-
nant histones was essentially carried out as described by Shim et al.44 Brieﬂy, all
four recombinant Xenopus laevis histones were co-expressed with N- and C-
terminal His6 tags in E. coli BL21 (DE3) pLysS cells (Novagen). Cells were grown at
37 °C in 2xYeast Extract Tryptone (YT) medium until OD600 reached 0.4, then
induced with 0.4 mM IPTG and grown at 37 °C for 20 h. Bacterial cells were
resuspended in 20 mM Tris-HCl pH 8.0, 2 M NaCl, 1 mM phenylmethylsulfonyl
ﬂuoride (PMSF) and 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), lysed, and the
soluble fractions loaded onto a 5 mL HisTrap column (GE Healthcare) pre-
equilibrated in the same buffer without PMSF. Following an initial washing step
with 20 mM Tris-HCl pH 8.0, 2 M NaCl, 30 mM imidazole, and 0.5 mM TCEP, the
octameric histone complex was eluted with the same buffer plus 500 mM imida-
zole. Fractions containing equivalent amounts of all four histone proteins were
pooled, and a corresponding volume of 20 mM Tris-HCl pH 8.0 and 0.5 mM TCEP
added in order to obtain a ﬁnal salt concentration of 1M. Thrombin protease (GE
Healthcare) at a concentration of 1 U per mg of protein was added to the histone
sample, and cleavage was carried out at room temperature for 48 h. Upon com-
pletion of the digestion, the octameric histone complex was puriﬁed on a Superdex
200 10/300 Increase column (GE Healthcare) and stored in 20 mM Tris-HCl pH
8.0, 2 M NaCl and 0.5 mM TCEP.
Nucleosome reconstitution. For the reconstitution of recombinant nucleosomes
used in activity assays, a 220 bp Widom 601 DNA sequence was ﬁrst ampliﬁed by
polymerase chain reaction (PCR) using unlabelled forward (gcgtaaGA-
TATCATCGATGGACCCTAT) and reverse (ttacgcGA-
TATCATCAGGTCGCTGTTC) primers (purchased from IDT). For the synthesis
of nucleosomes used in electrophoretic mobility shift assays, the same primers
described above were used with the exception that the forward primer was syn-
thesised with an IRDye®700 ﬂuorophore attached at the 5′-end of the sequence
(purchased from IDT). Following puriﬁcation of both PCR products by ethanol
precipitation and determination of the DNA concentration, nucleosome recon-
stitution was carried out as described in the EpiMark™ Nucleosome Assembly Kit
(New England Biolabs; https://www.neb.com/protocols/2012/06/04/epimark-
nucleosome-assembly-kit-e5350). Brieﬂy, 8 μM of histone octamer was mixed with
25 pmol of either unlabelled or labelled Widom 601 DNA in a total volume of
100 μL. The mixture was allowed to equilibrate for 1 h at room temperature, and
subsequently dialysed against Tris-EDTA (TE) buffers (20 mM Tris-HCl pH 8.0,
1 mM EDTA and 1mM DTT) containing 1, 0.6, and 0.25M NaCl. Each dialysis
step was carried out for 2–3 h at 4 °C, with the exception of the 0.6 M TE buffer
dialysis which was performed O/N at 4 °C. Reconstituted nucleosomes were further
dialysed against 20 mM Tris-HCl pH 8.0, 0.25 M NaCl and 1 mM DTT for 2–3 h at
4 °C, then subjected to a heat shift by incubation at 37 °C for 30 min9 and ﬁnally
stored at 4 °C.
Crystallisation and structure determination. Crystals of the
Calypso43–404–ASX207–340 complex (~4 mg/mL protein in 20 mM HEPES pH
7.5 and 100 mM NaCl) were grown in 60-well microbatch plates (Nunc InterMed,
Denmark) at 18 °C. Puriﬁed Calypso43–404–ASX207–340 was mixed with chymo-
trypsin at a ﬁnal concentration of 1 µg/mL immediately prior to crystallisation.
Plates were ﬁlled with 6 mL of Al’s Oil (Hampton Research), and drops were set up
manually by combining 1 μL of the puriﬁed complex with 1 μL of crystallisation
solution containing 0.1 M Bis-Tris propane pH 8.5, 0.0125M potassium iodide,
13% (w/v) PEG 3350 (Hampton Research) and 3% (v/v) MPD (Hampton
Research). Crystals grown under this condition were used to prepare a seeding
solution, which was then serially diluted (i.e. 1:10. 1:100, 1:1000, 1:10,000 and
1:100,000) into a new screen. Thicker crystals were obtained when the seeding
stock was diluted 1:10 in 0.1 M Bis-Tris propane pH 8.5, 0.05M potassium iodide,
13% (w/v) PEG 3350, and 10% (v/v) MPD. In this screen, drops were set up by
manually mixing 2 μL of the puriﬁed complex with 2 μL of buffer solution. The
resulting Calypso43–404–ASX207–340 crystals were harvested after one week and
cryoprotected with 20% (v/v) glycerol before ﬂash cooling in liquid nitrogen.
X-ray diffraction data were collected at 0.9537 Å, 100 K, on an Eiger 16M
detector at the MX2 beamline of the Australian Synchrotron. Data were processed
and scaled using XDS49 and exhibited strong anisotropy; therefore, an anisotropy-
corrected reﬂection ﬁle generated using the UCLA diffraction anisotropy correction
server50 was used for structure reﬁnement. The structure was solved by molecular
replacement with the programme Phaser-MR51 using the coordinates of the UCH-
L5–RPN13 complex (PDB code: 4UEM)16 as a search model. Structure reﬁnement
was performed with PHENIX reﬁne52 using the TLS function available within the
interface, while Coot53 was used to iteratively build missing residues. The structure
was solved in space group I121 at 3.5 Å resolution, with ﬁnal Rwork and Rfree values
of 24.4% and 29.4%, respectively. Ramachandran statistics show that 91.95% of
residues are in favoured regions, 7.90% in allowed regions, and 0.14% are outliers.
Statistics for data collection and reﬁnement of the structure are summarised in
Supplementary Table 1, while ﬁgures showing improvement of the electron density
map following anisotropy correction are included in Supplementary Figure 5b–e.
SAXS analysis. SAXS data collection was performed at the Australian Synchrotron
SAXS/WAXS beamline using an inline gel ﬁltration chromatography setup54,55.
Brieﬂy, 60 μL of the puriﬁed Calypso43–404–ASX207–340 complex at 8 mg/mL
(145 μM) was injected onto an inline Superdex 200 5/150 column (GE Healthcare)
and eluted at a ﬂow rate of 0.2 mL/min via a 1.5 mm glass capillary positioned in
the X-ray beam in 20 mM HEPES pH 7.5, 500 mM NaCl, 5% (v/v) glycerol, and
0.2 mM TCEP at 12 °C. Coﬂow SAXS was used to minimise sample dilution and
maximise signal to noise56.
Scattering data were collected in 2 s exposures over the course of the elution and
2D intensity plots with consistent scatter intensities from the peak of the SEC run
were radially averaged, normalised to sample transmission, and background
subtraction was performed using the Scatterbrain software (Stephen Mudie,
Australian Synchrotron). Background scatter was assessed by averaging scattering
proﬁles from earlier in the SEC run, before the protein was eluted. Guinier analysis
of each scatter pattern across the single elution peak showed consistent radius of
gyration (Rg) values, and superimposable patterns were averaged. Five proﬁles from
the apex of the elution peak were averaged, and the background subtracted using
Scatterbrain, to generate the averaged scatter patterns presented in the manuscript.
Guinier data analyses were performed using PRIMUS57. Indirect Fourier
transformation with GNOM58 was used to obtain the distance distribution
function, P(r), and the maximum dimension, Dmax, of the scattering particle.
CRYSOL59 was used to calculate theoretical scattering curves from the crystal
structure atomic coordinates and compare them with experimental scattering
curves. Statistics for data collection and analysis are reported in Supplementary
Table 5.
AUC analysis. AUC experiments were conducted in a Beckman model XL-I
instrument at a temperature of 20 °C. The puriﬁed Calypso43–404–ASX207–340
complex was analysed at ﬁnal concentrations ranging from 0.05 mg/mL (1 µM) to
2.2 mg/mL (40 µM) in 20 mM HEPES pH 7.8, 100 mM NaCl, and 0.8 mM TCEP.
For the sedimentation velocity experiment, 380 µL of sample and 400 µL of
buffer solution were loaded into separate sectors of the same quartz cell and
mounted in a Beckman 8-hole An-50 Ti rotor. Samples were centrifuged at a rotor
speed of 50,000 r.p.m. Data were collected at a single wavelength in continuous
mode, using a step-size of 0.003 cm without averaging. For the sedimentation
equilibrium experiment, 100 µL of sample and 120 µL of buffer solution were
loaded into separate sectors of the same quartz cell and mounted in a Beckman 8-
hole An-50 Ti rotor. Samples were centrifuged at rotor speeds of 8000, 12,000, and
16,000 r.p.m. Data were collected at a single wavelength in step mode, using a step-
size of 0.001 cm, averaging 20 data points.
Sedimentation velocity data at multiple time points were ﬁtted to a continuous
sedimentation-coefﬁcient model60,61 using the programme SEDFIT62. A van
Holde–Weischet analysis63 was performed for all runs, using the programme
UltraScan III64. Sedimentation equilibrium data were ﬁtted to a single species
model with mass conservation, as implemented in SEDPHAT65. The error in the
solution mass was estimated using the Monte-Carlo method as implemented in
SEDPHAT. Solvent density (1.006 g/ml at 20 °C) and viscosity (0.01002 p), and an
estimate of the partial speciﬁc volume of the protein (0.732 ml/g) were computed
using the amino acid composition and the programme SEDNTERP66.
SEC-MALLS analysis. To determine the oligomeric state of wild type and mutant
Calypso–ASX variants, SEC coupled to multi-angle laser light scattering (SEC-
MALLS) was used. Puriﬁed Calypso43–404–ASX207–340 wild type and mutant
proteins (in Fig. 3a, 60 μL of wild-type complex was used at 90 and 45 μM; in
Fig. 4c, 60 μL of each protein complex was injected at a concentration of ~50 μM)
were loaded at a ﬂow rate of 0.15 mL/min onto a Superdex 200 5/150 GL Increase
column (GE Healthcare) previously equilibrated in 20 mM HEPES pH 7.5 and
100 mM NaCl. The column was connected in line to a Dawn 8+MALLS detector
(Wyatt Technology) and a Waters 410 differential refractometer (Millipore). Data
were analysed using ASTRA version 5.3.4 software (Wyatt Technology).
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Analytical size-SEC analysis. The elution proﬁle of Calypso43–404–ASX207–340
wild type and mutant complexes was evaluated by injecting 60 μL of each puriﬁed
protein (at ~30–50 μM) over a Superdex 200 5/150 GL Increase column (GE
Healthcare) equilibrated in 20 mM HEPES pH 7.5 and 100 mM NaCl at a ﬂow rate
of 0.15 mL/min.
Crosslinking experiments. The functionality of the dimer interface in the
Calypso–ASX complex was conﬁrmed by using the amine cross-linker bis(sulfo-
succinimidyl)suberate, BS3 (Thermo Fisher Scientiﬁc). For time course experi-
ments, puriﬁed Calypso43–404–ASX207–340 wild type and L340A complexes (10 μM
each) were incubated with 0.5 mM BS3 at room temperature for up to 60 min. For
experiments with increased concentration of cross-linker, the same complexes were
incubated with 0.25, 0.5, and 1 mM BS3 at room temperature for 5 min. Reactions
were terminated by adding 50 mM Tris-HCl pH 8.0 into each sample, followed by a
second incubation step at room temperature for 15 min. All samples were resolved
on 16% SDS-PAGE gels and visualised using Coomassie Blue staining. Uncropped
gels for these experiments have been included in Supplementary Figs. 7 and 11.
Ubiquitin-H2Atail assays. Puriﬁed Ubiquitin-H2Atail (40 μM) was mixed with
Calypso43–471–ASX207–340 wild type or the indicated mutant complexes (50 nM
each) in assay buffer containing 25 mM HEPES pH 7.5, 150 mM NaCl, and 5 mM
DTT. Reactions were incubated for 4 h at 37 °C in a ﬁnal volume of 40 μL, and
samples were taken at the indicated time points. Reactions were terminated by the
addition of SDS-PAGE loading buffer containing β-mercaptoethanol. Proteins
were separated on 14–20% SDS-PAGE gradient gels, and visualised using Coo-
massie Blue staining. Uncropped gels are provided in Supplementary Fig. 11.
Ubiquitin-AMC assays. The activity of Calypso43–471–ASX207–340 and
BAP11–729–ASXL1247–366 was determined by monitoring the release of ﬂuorescent
7-amido-4-methylcoumarin (AMC) from the quenched Ubiquitin-AMC substrate,
providing a direct readout of DUB activity. Puriﬁed Ubiquitin-AMC powder
(UbiQ) was dissolved in pure DMSO to reach a concentration of 20 mg/mL, and
then slowly diluted with milliQ water to a ﬁnal concentration of 0.5 mg/mL. The
residual amount of DMSO left in the reaction was never above 2.5%. When a single
concentration of substrate was used, 0.5 nM of Calypso43–471–ASX207–340 wild type
or the indicated mutant complexes was mixed with 1 μM of Ubiquitin-AMC in a
ﬁnal volume of 10 μL. Reactions were performed in assay buffer (25 mM HEPES
pH 7.5, 150 mM NaCl, 5 mM DTT, and 0.05% Tween-20) at 25 °C using a black
384-well non-binding surface low ﬂange Cliniplate (Labsystems). Measurements
were taken every 20 s for 30 min in a CLARIOStar (BMG LABTECH) plate reader
using 380 and 460 nm excitation and emission wavelengths, respectively. To
determine kinetic parameters, 0.5 nM of the indicated Calypso43–471–ASX207–340 or
BAP11–729–ASXL1247–366 complexes were allowed to react with different con-
centrations of Ubiquitin-AMC (i.e. 0, 0.3, 0.6, 1.25, 2.5, 5, 10 μM) in 10 μL reac-
tions. Assays were performed as described above. Fluorescence intensity units were
converted to concentration of AMC released using free AMC (Sigma-Aldrich) as a
standard. Initial rates were calculated as the slope of the linear part of the reaction
curve, plotted against substrate concentration and ﬁtted to the Michaelis–Menten
equation using non-linear regression in Prism 7 (GraphPad Software).
Nucleosome DUB assays. Generation of nucleosomes mono-ubiquitinated at
Lys119 on Histone 2A was achieved by mixing 21 nM hUbe1, 150 nM UbcH5b3C/S,
40 nM Ring1B1–159–Bmi11–109, 2 μM 5-IAF-labelled wild-type Ubiquitin and
400–800 nM recombinant nucleosomes in assay buffer (20 mM Tris-HCl pH 7.5,
50 mM NaCl, 5 mM ATP, 2 mM MgCl2 and 2 mM DTT) for 4 h at 37 °C. The
reaction was then quenched by incubation with 0.2 U puriﬁed Apyrase (New
England Biolabs) for 10 min at 37 °C. Activity assays were performed in 10 μL
reactions at 37 °C using the indicated Calypso43–471–ASX207–340 and
BAP11–729–ASXL1247–366 proteins (~1.5 μM and ~500 nM for each Calypso–ASX
and BAP1–ASXL1 proteins, respectively) or wild-type Calypso43–404–ASX207–340
and BAP11–712–ASXL1247–366 complexes (~0.7–1 μM), and between 200 and 400
nM H2AK119Ub nucleosomes. Reactions were terminated by the addition of SDS-
PAGE loading buffer containing β-mercaptoethanol. Proteins were separated on
16% SDS-PAGE gels, and reactions were analysed on a Las-3000 (Fuji Film) imager
using the 5-IAF signal of 5-IAF labelled wild-type Ubiquitin. Reactions containing
No DUB and wild-type (i.e. WT) Calypso43–471–ASX207–340 or
BAP11–729–ASXL1247–366 complexes were performed in sextuplets, while samples
containing the indicated Calypso43–471–ASX207–340 or BAP11–729–ASXL1247–366
mutants were performed in triplicates. For each set of experiments, bands corre-
sponding to H2AK119Ub nucleosomes were quantiﬁed using Image Studio Lite
(LI-COR). Uncropped gels for Fig. 5b, c and Supplementary Fig. 6c are shown in
Supplementary Figs. 8, 9 and 11. Replicate gels are also included in Supplementary
Figs. 8 and 9.
Pulldown assays. To perform binding assays, His6-fused wild type and mutants
Calypso43–404–ASX207–340 complexes were ﬁrst immobilised on Ni2+-NTA resin.
Pulldown experiments were conducted by mixing the resin-bound
Calypso43–404–ASX207–340 variants with puriﬁed wild-type Ubiquitin in pulldown
buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, and 0.2%
(v/v) Tween-20. Reactions were set up in a ﬁnal volume of 200 μL, and incubated
for 1 h at 4 °C in rotation. The reaction mixtures were then centrifuged at 13,500 r.
c.f. for 2 min at 4 °C, and the resins were washed three times with pulldown buffer
prior to addition of reducing SDS-PAGE sample buffer. Samples were resolved on
16% SDS-PAGE gels, and visualised using Coomassie Blue staining (refer to
Supplementary Fig. 11 for the uncropped gel).
Electrophoretic mobility shift assays. Recombinant unmodiﬁed nucleosomes
(40–80 nM), reconstituted with the labelled Widom 601 220 bp DNA sequence,
were incubated with increased concentrations of the indicated
Calypso43–404–ASX207–340, Calypso43–471–ASX207–340, or
BAP11–729–ASXL1247–366 complexes in assay buffer containing 10 mM HEPES pH
7.5, 100 mM NaCl, 0.1 mM DTT, and 5% (v/v) glycerol. Concentrations of 0.5, 1,
2, 4, and 8 μM were used for each Calypso–ASX complex, while 0.1, 0.2, 0.5, 1, and
2 μM were employed for BAP11–729–ASXL1247–366. Assays were incubated for 1 h
at room temperature in a ﬁnal volume of 10 μL. Samples were analysed using native
PAGE gel electrophoresis on 4–12% polyacrylamide gels, which were run for 2–3 h
at 125 V in 25 mM Tris-HCl and 20 mM glycine at 4 °C. The gels were pre-run in
the same buffer for at least 1 h at 125 V and 4 °C prior to sample loading. Bands
were visualised on an Odyssey FC Imaging system (LI-COR) at 700 nm with a
10 min exposure. Reactions containing wild type and mutant
Calypso43–471–ASX207–340 and BAP11–729–ASXL1247–366 complexes were per-
formed in triplicates, and bands corresponding to the shifted nucleosomes were
quantiﬁed using Image Studio Lite (LI-COR). The uncropped gel for Fig. 6a is
shown in Supplementary Fig. 7, while replicate gels for Fig. 6b, c are provided in
Supplementary Fig. 10.
Figure generation. All structural ﬁgures, including the electrostatic potential
molecular surface of the nucleosome particle shown in Fig. 6e and the structure
overlays shown in Supplementary Fig. 2, were created using PyMOL (The PyMOL
Molecular Graphics System, Version 1.8.6.2 Schrödinger, LLC). Mapping of the
BAP1 missense mutations onto the Calypso43–404–ASX207–340 structure shown in
Fig. 2a was achieved using the loadBfacts.py script for PyMOL (https://pymolwiki.
org/index.php/Load_new_B-factors). Electron density maps shown in Supple-
mentary Fig. 3a and in Supplementary Fig. 5c were calculated using the Fast
Fourier Transform (FFT) algorithm67,68 within the CCP4 program suite69. Com-
posite omit maps shown in Supplementary Fig. 5b, d were calculated with PHE-
NIX52 and FFT67–69. All maps were then overlaid onto the cartoon representation
of the Calypso43–404–ASX207–340 structure in PyMOL. Analysis of the interaction
surfaces in the Calypso43–404–ASX207–340 complex (see Supplementary Table 4)
was performed using the European Bioinformatics Institute (EBI) web service of
the Proteins, Interfaces, Structures and Assemblies (PISA) software (http://www.
ebi.ac.uk/pdbe/pisa/)38. Graphs shown in Figs. 2c, 5, 6b, c and Supplementary
Fig. 6b, as well as the representation of SAXS data shown in Fig. 4d and in
Supplementary Fig. 5f were created using Prism 7 (GraphPad Software), while the
elution proﬁles obtained from SEC-MALLS experiments (see Figs. 3a and 4c) were
generated using Plot2 (Plot2, Version 2.0.8; http://plot.micw.eu/). AUC plots
shown in Fig. 3b, c and in Supplementary Fig. 4 were generated using Origin
(OriginLab, Northampton, MA). Sequence alignments shown in Fig. 2b, Supple-
mentary Figs. 1b–d and 6a were created using Aline, Version 1.0.025 (ref. 70). All
ﬁgure panels were assembled using Adobe Illustrator CS4, Version 14.0.0 (Adobe
Systems).
Quantiﬁcation and statistical analysis. Statistics for X-ray data collection and
reﬁnement are summarised in Supplementary Table 1, values obtained by PISA for
the analysis of the crystallographic interfaces in the Calypso43–404–ASX207–340
structure are reported in Supplementary Table 4, and statistics for SAXS data
collection and analysis are summarised in Supplementary Table 5. Experiments
shown in Figs. 2c, 5a, and in Supplementary Fig. 6b were performed twice, with
error bars either indicating the range of measurement (Fig. 2c) or ±SEM (Fig. 5a
and Supplementary Fig. 6b). Experiments shown in Fig. 5b, c were performed in
sextuplets (for the No DUB and WT reactions) or triplicates (for reactions con-
taining Calypso–ASX and BAP1–ASXL1 mutant complexes) while experiments
shown in Fig. 6b, c were performed in triplicates, and the values corresponding to
the six or three independent experiments with a line passing through the mean are
shown.
Data availability
The atomic coordinates and structure factors for the Calypso43–404–ASX207–340 complex
have been deposited to the Protein Data Bank under ID code 6CGA. All data supporting
the ﬁndings in this study are available within the article and in the Supplementary
Information Files, and are available from the corresponding author upon reasonable
request.
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